LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
Patent Owner
Stats
- 25 US PATENTS IN FORCE
- 10 US APPLICATIONS PENDING
- Jan 23, 2018 most recent publication
Details
- 25 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 808 Total Citation Count
- Jan 27, 1993 Earliest Filing
- 39 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2018/0016,345 LIGHT INHIBITORS FOR SCLERODERMA AND SKIN FIBROTIC DISEASE TREATMENTFeb 05, 16Jan 18, 18[A61K, C07K]
2017/0184,612 USE OF LEUKOCYTES AND NOVEL BIOMARKERS IN THE DIAGNOSIS, CONFIRMATION, AND TREATMENT OF A NEUROLOGICAL DISORDERApr 03, 15Jun 29, 17[A61K, G01N]
2017/0058,037 LIGHT INHIBITORS FOR ASTHMA, LUNG AND AIRWAY INFLAMMATION, RESPIRATORY, INTERSTITIAL, PULMONARY AND FIBROTIC DISEASE TREATMENTOct 14, 16Mar 02, 17[A61K, C07K]
2016/0075,753 MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C-etaApr 30, 14Mar 17, 16[C12N, C07K]
2015/0110,819 T CELL EPITOPES FROM COCKROACH AND METHODS OF MAKING AND USING SAMEMay 03, 13Apr 23, 15[A61K, G01N, C07K]
2015/0023,992 TIMOTHY GRASS ALLERGENS AND METHODS AND USES FOR IMMUNE RESPONSE MODULATIONFeb 07, 13Jan 22, 15[C07K]
2014/0004,151 Antigens and Epitopes Derived From Mycobacterium TuberculosisOct 01, 12Jan 02, 14[A61K, C07K]
2013/0108,602 METHODS AND USES OF NUR77 AND NUR77 AGONISTS TO MODULATE MACROPHAGES AND MONOCYTES, AND TREAT INFLAMMATION, INFLAMMATORY DISEASE AND CARDIOVASCULAR DISEASEOct 05, 12May 02, 13[A61K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9873744 Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying sameJan 13, 15Jan 23, 18[A61K, C07K]
9771419 Antagonistic human light-specific human monoclonal antibodiesFeb 02, 15Sep 26, 17[A61K, C07K]
9700606 HVEM/BTLA, HVEM/CD 160 and HVEM/gD cis complexes and methods of useJul 08, 09Jul 11, 17[A61K, C07K]
9694058 Light-mediated anti-cell proliferative compositions and methodsOct 25, 07Jul 04, 17[A61K, C12N, C07K]
9447172 Vaccinia virus H3L and B5R specific monoclonal antibodies and methods of making and using sameDec 27, 13Sep 20, 16[A61K, C07K]
9301994 LIGHT inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatmentJan 20, 11Apr 05, 16[A61K]
8974787 Antagonistic human light-specific human monoclonal antibodiesMay 08, 13Mar 10, 15[A61K, C07K]
8956615 Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying sameSep 13, 13Feb 17, 15[A61K, C07K]
8623370 Vaccinia virus H3L and B5R specific monoclonal antibodies and methods of making and using sameOct 06, 08Jan 07, 14[A61K]
8551477 Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying sameDec 19, 11Oct 08, 13[A61K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2016/0287,696 PAN POLLEN IMMUNOGENS AND METHODS AND USES FOR IMMUNE RESPONSE MODULATIONAbandonedNov 20, 14Oct 06, 16[A61K, C07K]
2015/0150,960 PROTECTION AGAINST DENGUE VIRUS AND PREVENTION OF SEVERE DENGUE DISEASEAbandonedJun 25, 12Jun 04, 15[A61K, C12N]
2015/0119,333 METHODS OF INHIBITING ADVERSE CARDIAC EVENTS AND TREATING ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE USING GALECTIN-3 BINDING PROTEIN (GAL-3BP, BTBD17B, MAC-2 BINDING PROTEIN)AbandonedSep 18, 13Apr 30, 15[A61K]
2015/0004,189 EPITOPES FROM ALLERGEN PROTEINS AND METHODS AND USES FOR IMMUNE RESPONSE MODULATIONAbandonedFeb 07, 13Jan 01, 15[A61K, G01N]
2014/0186,372 COMPOSITIONS TARGETING PKC-THETA AND USES AND METHODS OF TREATING PKC-THETA PATHOLOGIES, ADVERSE IMMUNE RESPONSES AND DISEASESAbandonedJun 15, 12Jul 03, 14[G01N]
2014/0134,647 NOVEL CRYSTAL STRUCTURE AND LIGAND BINDING SITES OF TRAIL RECEPTORAbandonedOct 31, 13May 15, 14[G01N]
2013/0202,634 Dengue Virus (DV) Polypeptide Sequences, T Cell Epitopes and Methods and Uses ThereofAbandonedDec 18, 12Aug 08, 13[C07K]
2013/0171,164 COMPOSITIONS AND METHODS OF MODULATING RECEPTOR PROTEIN TYROSINE PHOSPHATASESAbandonedAug 02, 12Jul 04, 13[C12Q]
2013/0095,127 METHODS OF INHIBITING INFLAMMATION AND INFLAMMATORY DISEASES USING Gal-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN)AbandonedSep 26, 12Apr 18, 13[A61K, C07K]
2013/0084,293 HISTAMINE-RELEASING FACTOR (HRF), HRF-RECEPTOR AND METHODS OF MODULATING INFLAMMATIONAbandonedSep 28, 12Apr 04, 13[A61K, C07K]
2012/0251,505 HUMAN LYMPHOID TISSUE INDUCER (LTi) CELL COMPOSITIONS AND METHODS OF USEAbandonedSep 03, 10Oct 04, 12[A61K, C12Q, C12N, G01N, A61P, C40B]
2012/0121,590 METHODS OF INHIBITING ADVERSE CARDIAC EVENTS AND TREATING ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE USING GALECTIN-3 BINDING PROTEIN (GAL-3BP, BTBD17B, MAC-2 BINDING PROTEIN)AbandonedApr 16, 10May 17, 12[A61K, C12Q, G01N, A61P, C07K]
2011/0171,242 LIGAND FOR HERPES SIMPLEX VIRUS ENTRY MEDIATOR AND METHODS OF USEAbandonedJul 06, 09Jul 14, 11[A61K, C12N, A61P, C07K]
2011/0150,914 COMPOSITIONS AND METHODS FOR DENGUE VIRUS (DV) TREATMENT AND VACCINATIONAbandonedJun 09, 09Jun 23, 11[A61K, C07H, C12N, A61P, C07K]
2011/0038,855 TRAIL AND METHODS OF MODULATING T CELL ACTIVITY AND ADAPTIVE IMMUNE RESPONSES USING TRAILAbandonedApr 02, 09Feb 17, 11[A61K, C12N, A61P]
2010/0129,389 METHODS OF MODULATING HVEM, BTLA AND CD160 CIS COMPLEX RESPONSE OR SIGNALING ACTIVITY WITH SOLUBLE LIGHT POLYPEPTIDE SEQUENCESAbandonedAug 03, 09May 27, 10[A61K, A61P]
2009/0136,470 REGULATORY T CELLS AND METHODS OF MAKING AND USING SAMEAbandonedJun 13, 08May 28, 09[A61K]
2009/0136,427 LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease TreatmentAbandonedSep 18, 08May 28, 09[A61K, A61P]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
